<DOC>
	<DOC>NCT00242307</DOC>
	<brief_summary>The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with asthma. Roflumilast will be administered orally once daily. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.</brief_summary>
	<brief_title>Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main inclusion criteria: Adult patients with bronchial asthma meeting the Guideline for Prevention and Control of Asthma 2003 (JGL 1998, revised 2nd edition) No change in asthma treatment during the last 4 weeks prior to the registration Nonsmokers or exsmokers for 12 months or more %FEV1 ranging between 60 and 80% Main exclusion criteria: Patients with poorly controlled asthma Inhalation therapy exceeding low dose during 4 weeks prior to the registration Concurrent respiratory diseases such as COPD considered to affect the efficacy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>phosphodiesterase 4 inhibitor</keyword>
</DOC>